Table I.
Characteristics of study populationa
| Dead (N = 64) | Alive (N = 252) | P-value | Recurrence (N = 56) | No recurrence (N = 181) | P-value | |
| Sex, N (%) | ||||||
| Male | 42 (65.63) | 164 (65.08) | 0.94 | 40 (71.43) | 115 (63.54) | 0.28 |
| Female | 22 (34.38) | 88 (34.92) | 16 (28.57) | 66 (36.46) | ||
| Ethnicity, N (%) | ||||||
| White | 54 (84.38) | 206 (81.75) | 0.82 | 46 (82.14) | 146 (80.66) | 0.48 |
| Hispanic | 2 (3.13) | 12 (4.76) | 1 (1.79) | 10 (5.52) | ||
| Black | 8 (12.50) | 34 (13.49) | 9 (16.07) | 25 (13.81) | ||
| Age, mean (SD) | 59.36 (10.21) | 58.88 (10.57) | 0.75 | 59.36 (9.74) | 59.37(10.83) | 0.99 |
| Smoking status, N (%) | ||||||
| Never | 28 (43.75) | 133 (52.78) | 0.41 | 31 (55.36) | 93 (51.38) | 0.63 |
| Former | 27 (42.19) | 86 (34.13) | 17 (30.36) | 67 (37.02) | ||
| Current | 9 (14.06) | 33 (13.10) | 8 (14.29) | 21 (11.60) | ||
| Pack-years, mean (SD) | 26.47 (31.39) | 28.78 (23.82) | 0.64 | 39.42 (33.20) | 24.91 (21.32) | 0.01 |
| Stage, N (%) | ||||||
| I | 6 (9.38) | 128 (53.33) | <0.001 | 4 (7.14) | 111 (65.29) | <0.001 |
| II | 5 (7.81) | 20 (8.33) | 7 (12.50) | 15 (8.82) | ||
| III | 19 (29.69) | 60 (25.00) | 36 (64.29) | 40 (23.53) | ||
| IV | 34 (53.13) | 32 (13.33) | 9 (16.07) | 4 (2.35) | ||
| Grade, N (%) | ||||||
| I | 0 (0.00) | 3 (1.19) | <0.001 | 0 (0.00) | 2 (1.10) | <0.001 |
| II | 7 (10.94) | 79 (31.35) | 8 (14.29) | 69 (38.12) | ||
| III | 22 (34.38) | 126 (50.00) | 23 (41.07) | 90 (49.72) | ||
| IV | 35 (54.69) | 38 (15.08) | 25 (44.64) | 14 (7.73) | ||
| Unknown | 0 (0.00) | 6 (2.38) | 0 (0.00) | 6 (3.31) | ||
| Tumor size, mean (SD) | 9.30 (4.14) | 6.03 (3.78) | <0.001 | 9.68 (3.58) | 5.24 (3.39) | <0.001 |
| Histology, N (%) | ||||||
| Conventional | 55 (85.44) | 199 (78.97) | 0.21 | 46 (82.14) | 145 (80.11) | 0.74 |
| Other | 9 (14.06) | 53 (21.03) | 10 (17.86) | 36 (19.89) | ||
| Cytokine treatment, N (%) | ||||||
| Yes | 15 (23.81) | 6 (2.44) | <0.001 | 0 | 1 (0.56) | 0.58 |
| No | 48 (76.19) | 240 (97.56) | 55 (100.00) | 179 (99.44) | ||
| Chemotherapy, N (%) | ||||||
| Yes | 11 (17.46) | 16 (6.45) | 0.006 | 6 (10.91) | 5 (2.78) | 0.012 |
| No | 52 (82.54) | 232 (93.55) | 49 (89.09) | 175 (97.22) | ||
| Molecular targeted therapy, N (%) | ||||||
| Yes | 7 (11.11) | 17 (6.85) | 0.26 | 1 (1.82) | 3 (1.67) | 0.94 |
| No | 56 (88.89) | 231 (93.15) | 54 (98.18) | 177 (98.33) | ||
| Radiotherapy, N (%) | ||||||
| Yes | 2 (3.17) | 3 (1.22) | 0.27 | 0 (0.00) | 1 (0.56) | 0.58 |
| No | 61 (96.83) | 243 (98.78) | 55 (100.00) | 179 (99.44) | ||
a
Numbers in some categories do not add up to total due to missing values